716 related articles for article (PubMed ID: 19595447)
1. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
[TBL] [Abstract][Full Text] [Related]
3. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
De Hert M; Correll CU; Cohen D
Schizophr Res; 2010 Mar; 117(1):68-74. PubMed ID: 20060684
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
7. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic treatment and mortality in schizophrenia.
Torniainen M; Mittendorfer-Rutz E; Tanskanen A; Björkenstam C; Suvisaari J; Alexanderson K; Tiihonen J
Schizophr Bull; 2015 May; 41(3):656-63. PubMed ID: 25422511
[TBL] [Abstract][Full Text] [Related]
11. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.
Rubio JM; Kane JM; Tanskanen A; Tiihonen J; Taipale H
Lancet Psychiatry; 2024 Jun; 11(6):443-450. PubMed ID: 38697177
[TBL] [Abstract][Full Text] [Related]
12. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
13. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
15. All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.
Tenback D; Pijl B; Smeets H; Os Jv; Harten Pv
J Clin Psychopharmacol; 2012 Feb; 32(1):31-5. PubMed ID: 22198442
[TBL] [Abstract][Full Text] [Related]
16. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.
Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752
[TBL] [Abstract][Full Text] [Related]
19. The unchanging mortality gap for people with schizophrenia.
Chwastiak LA; Tek C
Lancet; 2009 Aug; 374(9690):590-2. PubMed ID: 19595448
[No Abstract] [Full Text] [Related]
20. Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission.
Valevski A; Gilat Y; Olfson M; Benaroya-Milshtein N; Weizman A
Int Clin Psychopharmacol; 2012 May; 27(3):159-64. PubMed ID: 22466059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
